The TMPRSS2-ERG gene fusion blocks XRCC4-mediated nonhomologous end-joining repair and radiosensitizes prostate cancer cells to PARP inhibition

Molecular Cancer Therapeutics

Volumn 14, Issue 8, 2015, Pages 1896-1906

  Chatterjee, Payel ^a,b   Choudhary, Gaurav S ^a,c   Alswillah, Turkeyah ^d   Xiong, Xiahui ^c   Heston, Warren D ^a   Magi Galluzzi, Cristina ^a   Zhang, Junran ^c   Klein, Eric A ^a   Almasan, Alexandru ^a,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b KENT STATE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CLEVELAND STATE UNIVERSITY   (United States)

^e TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DEPENDENT PROTEIN KINASE; HISTONE H2AX; HYBRID PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RAD51 PROTEIN; SERINE; SMALL INTERFERING RNA; THREONINE; TMPRSS2 ERG FUSION PROTEIN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; XRCC4 PROTEIN; CHROMATIN; DNA BINDING PROTEIN; MDC1 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; XRCC4 PROTEIN, HUMAN;

ARTICLE; AUTOPHOSPHORYLATION; CHROMATIN; CONTROLLED STUDY; DNA DAMAGE; DNA END JOINING REPAIR; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; GENE FUSION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIZATION; CELL CYCLE CHECKPOINT; DRUG EFFECTS; GENETICS; MALE; METABOLISM; PROSTATE TUMOR; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR CELL LINE;

CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CHROMATIN; DNA DAMAGE; DNA END-JOINING REPAIR; DNA-BINDING PROTEINS; HUMANS; MALE; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; TRANS-ACTIVATORS;

EID: 84942134533     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0865     Document Type: Article

References (50)

1. Rowley JD. Molecular cytogenetics: Rosetta stone for understanding cancer - twenty-ninth G. H. A. Clowes memorial award lecture. Cancer Res 1990;50:3816-25.
2. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-41.
3. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
4. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J , et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-8.
5. Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, et al. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade postatic intraepithelial noplasia. J Clin Oncol 2014;32:206-211.
6. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006;66:10242-6.
7. Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006;8:465-9.
8. Teixeira MR. Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions. Am J Surg Pathol 2008;32:642-4.
9. Mani RS, Tomlins SA, Callahan K, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009;326:1230.
10. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010;42:668-75.
11. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009;139:1069-83.
12. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011;19:664-78.
13. Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, Ciezki J, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE 2013;8:e60408.
14. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 2003;63:4713-23.
15. Riballo E, Kuhne M, Rief N, Doherty A, Smith GC, Recio MJ, et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 2004;16:715-24.
16. Groth P, Orta ML, Elvers I, Majumder MM, Lagerqvist A, Helleday T. Homologous recombination repairs secondary replication induced DNA double-strand breaks after ionizing radiation. Nucleic Acids Res 2012;40:6585-94.
17. Martin OA, Ivashkevich A, Choo S, Woodbine L, Jeggo PA, Martin RF, et al. Statistical analysis of kinetics, distribution and co-localisation of DNA repair foci in irradiated cells: cell cycle effect and implications for prediction of radiosensitivity. DNA Repair 2013;12:844-55.
18. Davis AJ, Chen DJ. DNA double strand break repair via non-homologous end-joining. Transl Cancer Res 2013;2:130-43.
19. Gottlieb TM, Jackson SP. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 1993;72:131-42.
20. Lieber MR, Wilson TE. SnapShot: nonhomologous DNA end joining (NHEJ). Cell 2010;142:496-.e1.
21. Hammel M, Rey M, Yu Y, Mani RS, Classen S, Liu M, et al. XRCC4 protein interactions with XRCC4-like factor (XLF) create an extended grooved scaffold for DNA ligation and double strand break repair. J Biol Chem 2011;286:32638-50.
22. Neal JA, Sugiman-Marangos S, Vandervere-Carozza P, Wagner M, Turchi J, Lees-Miller SP, et al. Unraveling the complexities of DNA-PK autophosphorylation. Mol Cell Biol 2014;34:2162-75.
23. Feng Z, Zhang J. A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest. Nucleic Acids Res 2012;40:726-38.
24. Chen H, Ma Z, Vanderwaal RP, Feng Z, Gonzalez-Suarez I, Wang S, et al. The mTOR inhibitor rapamycin suppresses DNA double-strand break repair. Radiat Res 2011;175:214-24.
25. Zhang J, Ma Z, Treszezamsky A, Powell SN. MDC1 interacts with Rad51 and facilitates homologous recombination. Nat Struct Mol Biol 2005;12:902-9.
26. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999;13:2633-8.
27. Drouet J, Delteil C, Lefrancois J, Concannon P, Salles B, Calsou P. DNA-dependent protein kinase and XRCC4-DNA ligase IV mobilization in the cell in response to DNA double strand breaks. J Biol Chem 2005;280:7060-9.
28. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clinical Oncol 2011;29:3659-68.
29. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 2008;68:8516-24.
30. Cui X, Yu Y, Gupta S, Cho YM, Lees-Miller SP, Meek K. Autophosphorylation of DNA-dependent protein kinase regulates DNA end processing and may also alter double-strand break repair pathway choice. Mol Cell Biol 2005;25:10842-52.
31. 2 arrest response to genotoxic stress in prostate carcinoma. Oncogene 2007;26:1897-909.
32. 2 phase cells. Cell Cycle 2007;6:1682-6.
33. Lunardi A, Varmeh S, Chen M, Taulli R, Guarnerio J, Ala U, et al. Suppression of CHK1 by ETS family members promotes DNA damage response bypass and tumorigenesis. Cancer Dscov 2015;5:550-63.
34. Burma S, Chen BP, Chen DJ. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair 2006;5:1042-8.
35. Neal JA, Dang V, Douglas P, Wold MS, Lees-Miller SP, Meek K. Inhibition of homologous recombination by DNA-dependent protein kinase requires kinase activity, is titratable, and is modulated by autophosphorylation. Mol Cell Biol 2011;31:1719-33.
36. Uematsu N, Weterings E, Yano K, Morotomi-Yano K, Jakob B, Taucher-Scholz G, et al. Autophosphorylation of DNA-PKCS regulates its dynamics at DNA double-strand breaks. J Cell Biol 2007;177:219-29.
37. Harding SM, Bristow RG. Discordance between phosphorylation and recruitment of 53BP1 in response to DNA double-strand breaks. Cell Cycle 2012;11:1432-44.
38. Chatterjee P, Plesca D, Mazumder S, Boutros J, Yannone SM, Almasan A. Defective chromatin recruitment and retention of NHEJ core components in human tumor cells expressing a Cyclin E fragment. Nucleic Acids Res 2013;41:10157-69.
39. Lee JH, Cheong HM, Kang MY, Kim SY, Kang Y. Ser1778 of 53BP1 Plays a Role in DNA Double-strand Break Repairs. Korean J Physiol Pharmacol 2009;13:343-8.
40. Munoz IM, Jowsey PA, Toth R, Rouse J. Phospho-epitope binding by the BRCT domains of hPTIP controls multiple aspects of the cellular response to DNA damage. Nucleic Acids Res 2007;35:5312-22.
41. Minter-Dykhouse K, Ward I, Huen MSY, Chen J, Lou ZK. Distinct versus overlapping functions of MDC1 and 53BP1 in DNA damage response and tumorigenesis. J Cell Biol 2008;181:727-35.
42. Cottarel J, Frit P, Bombarde O, Salles B, Négrel A, Bernard S, et al. A noncatalytic function of the ligation complex during nonhomologous end joining. J Cell Biol 2013;200:173-86.
43. Pellecchia A, Pescucci C, De Lorenzo E, Luceri C, Passaro N, Sica M, et al. Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition. Oncogenesis 2012;1:e20.
44. Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, et al. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res 2013;19:5202-9.
45. Han S, Brenner JC, Sabolch A, Jackson W, Speers C, Wilder-Romans K, et al. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Neoplasia 2013;15:1207-17.
46. Bartkova J, Horejsi Z, Koed K, Krämer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
47. Jorgensen TJ. Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther 2009;8:665-70.
48. Iliakis G. Backup pathways of NHEJ in cells of higher eukaryotes: cell cycle dependence. Radiother Oncol 2009;92:310-5.
49. Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov 2013;3:1254-71.
50. Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013;3:1245-53.